Invention Grant
- Patent Title: Treating sickle cell disease with a pyruvate kinase R activating compound
-
Application No.: US17275741Application Date: 2019-09-19
-
Publication No.: US12053458B2Publication Date: 2024-08-06
- Inventor: Anna Ericsson , Neal Green , Gary Gustafson , David R. Lancia, Jr. , Bingsong Han , Lorna Mitchell , David Richard , Zhongguo Wang , Tatiana Shelekhin , Chase C. Smith , Xiaozhang Zheng
- Applicant: Novo Nordisk Health Care AG
- Applicant Address: CH Zurich
- Assignee: Novo Nordisk Health Care AG
- Current Assignee: Novo Nordisk Health Care AG
- Current Assignee Address: CH Zurich
- Agent Jianjie Hu
- International Application: PCT/US2019/052024 2019.09.19
- International Announcement: WO2020/061378A 2020.03.26
- Date entered country: 2021-03-12
- Main IPC: A61K31/436
- IPC: A61K31/436 ; A61K9/00 ; A61P7/06 ; C07D487/04 ; C07D491/056
Abstract:
Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
Public/Granted literature
- US20220031671A1 TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND Public/Granted day:2022-02-03
Information query
IPC分类:
